SBIR/STTR Research Award
Not Available
Award amount
$299,456Program and phase
SBIR · Phase IAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CANCER THERAPEUTICS LABORATORIES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- KS2BU4J2PHE3
- Solicitation number
- PHS2010-1
- Topic code
- NCI
Research abstract
In the last decade, monoclonal antibody immunotherapy has established itself as a front-line treatment of human cancer. One such antibody, Erbituz (cetuzimab), has been used to treat epidermal growth factor receptor positive (EGFR+) tumors due to its ability to inhibit tumor growth by blocking EGFR signaling required for cell proliferation. In this proposal, a generic anticody, designated ch225, will be generated to provide the medical community with a cost effective alternative product for Erbitux.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- OTHER FUNCTIONS SBIR PHASE II TOPIC 275, GENERIC ERBITUX FOR TREATMENT OF EGFR+ CANCER
- Monoclonal Antibodies Against T-Regulatory Cells
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
3 SBIR/STTR records share this UEI (2004–2012). Reported award amounts total $3,419,016. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services